Winder Laboratories Initiates Nationwide Class II Recall for Phenazopyridine HCl Due to Phenobarbital Mix-Up
Winder Laboratories, LLC has issued a Class II nationwide recall for Phenazopyridine HCl Tablets USP 100 mg due to a critical product mix-up, with bottles containing Phenobarbital tablets. This event, impacting 5,676 bottles, mandates immediate supply chain review and underscores the imperative for robust quality control and supplier diversification to mitigate significant regulatory and patient safety risks.
Critical Product Mix-Up Triggers Nationwide Class II Recall for Winder Laboratories
Winder Laboratories, LLC, based in Winder, GA, United States, has initiated a voluntary, firm-initiated Class II recall (D-0545-2024) for its Phenazopyridine HCl Tablets USP 100 mg. The critical issue identified is a product mix-up where bottles labeled as Phenazopyridine HCl were found to contain Phenobarbital tablets 16.2 mg. This represents a significant deviation from Good Manufacturing Practices (GMP) and poses a direct risk to patient safety, as Phenobarbital is a barbiturate with different therapeutic indications and potential for serious adverse effects if taken unknowingly. The recall specifically impacts Lot#: 1142404, with an expiration date of February 27, 2027. The FDA classified this event on June 7, 2024, following the firm's initial notification via e-mail on May 28, 2024. For procurement directors and regulatory affairs heads, this incident at Winder Laboratories necessitates an immediate review of inbound quality control procedures for all pharmaceutical products, especially those from contract manufacturers or new suppliers. The presence of an entirely different active pharmaceutical ingredient (API) in a finished product bottle highlights severe lapses in manufacturing and packaging controls. This level of error can lead to patient harm, product liability issues, and significant brand damage. Business development executives should note the potential for market disruption and the need for robust supplier auditing to prevent similar catastrophic quality failures from impacting their product portfolios.
Supply Chain Exposure: Nationwide Distribution of Affected Phenazopyridine HCl
The recall encompasses 473 cases, totaling 5,676 bottles of Phenazopyridine HCl Tablets USP 100 mg, distributed nationwide within the United States. This broad distribution pattern means that numerous downstream distributors, pharmacies, and ultimately, patients across the country are potentially exposed to this mislabeled product. The scale of the recall underscores the extensive reach of Winder Laboratories' supply chain for this specific product. For supply chain VPs, the immediate business imperative is to identify and quarantine all affected lots of Phenazopyridine HCl from Winder Laboratories. This includes verifying inventory across all distribution centers, retail pharmacies, and any secondary markets. Regulatory affairs teams must ensure strict adherence to FDA recall procedures, including effective communication with affected customers and proper disposition of recalled products. The financial implications extend beyond the direct costs of the recall, encompassing potential returns, chargebacks, and the erosion of trust in the supplier. Business development executives should assess the competitive landscape for Phenazopyridine HCl, as this recall may create opportunities for alternative suppliers to gain market share if Winder Laboratories faces prolonged operational or reputational challenges.
Mitigating Supply Risk: Strategic Sourcing for Phenazopyridine HCl
The current recall by Winder Laboratories, LLC, for Phenazopyridine HCl due to a product mix-up, highlights the critical vulnerabilities inherent in pharmaceutical supply chains, particularly when relying on single or limited sources. While our intelligence graph does not currently list alternative suppliers for Phenazopyridine HCl, this event serves as a stark reminder for procurement directors to proactively identify and qualify multiple sources for essential APIs and finished drug products. For businesses reliant on Winder Laboratories for Phenazopyridine HCl, immediate action is required to assess current inventory levels and potential supply gaps. Supply chain VPs must initiate a strategic review of their supplier diversification strategies, focusing on geographic diversity and robust qualification processes that include rigorous on-site audits of quality management systems. Qualification timelines for new suppliers can range from 6 to 18 months, depending on the complexity of the molecule and regulatory requirements, emphasizing the need for proactive planning. Business development executives should explore partnerships with manufacturers demonstrating impeccable quality records to secure future supply and minimize exposure to similar regulatory disruptions, ensuring product availability and market stability.
Regulatory Outlook: Post-Recall Scrutiny for Winder Laboratories
Although the recall for Phenazopyridine HCl Tablets USP 100 mg is listed as 'Completed' by the FDA, this status primarily indicates that Winder Laboratories has executed its recall plan, including notification and product retrieval. It does not signify the resolution of the underlying quality system deficiencies that led to the product mix-up. A Class II recall, especially one involving the substitution of a different active pharmaceutical ingredient like Phenobarbital, typically triggers intense FDA scrutiny and follow-up inspections. Regulatory affairs heads should anticipate that the FDA will conduct a thorough investigation into Winder Laboratories' manufacturing processes, quality control, and packaging operations to identify the root cause of this severe error. This will likely result in observations on a Form 483, and potentially a Warning Letter, if systemic issues are found. Procurement directors should demand comprehensive corrective and preventive action (CAPA) plans from Winder Laboratories, detailing how such mix-ups will be prevented in the future, before considering any resumption of sourcing. The long-term implications for Winder Laboratories could include operational restrictions, reputational damage, and a significant impact on their ability to secure new contracts, directly affecting the stability of their supply for existing customers.